33752 Federal Register / Vol. 61, No. 126 / Friday, June 28, 1996 / Notices

which would build a temporary

database of information collected by

States on newly hired employees for

matching activities with cases in locate

status within the FPLS and cases

certified for Federal tax refund offset.

This collection responds to President

Clinton’s June 18, 1996, executive

action on welfare reform announcing a

new pilot program that will help track

those parents who cross state lines to

avoid their child support obligation.

Under the pilot, States which currently

have new hire reporting programs in

place would voluntarily send their

existing record data via computer tape,

formatted according to either the State’s

or Administration for Children and

Families’s (ACF) specifications, to the

Federal Parent Locate Service within

OCSE. These records will be stored in

a temporary database to be matched

against case data in the FPLS, and the

Tax Refund Offset System (TROS).

When a match is made, the ACF Office

will contact the absent parent’s current

state of residence where a match was

found so that the state child support

agency can take appropriate action. In

turn, States will be asked to submit

periodic tracking and reporting

information on the success of the pilot

matching.

Respondents: State governments.

Annual Burden Estimates:

Instrument Number of

respondents

Number of responses per

respondent

Average burden hours per

response

Total burden

hours

Standard Forms ................................................................................................ 25 1 8 200

Estimated Total Annual Burden

Hours: 200.

Explanation

• The specific number of estimated

annual burden hours per State will vary

depending on individual circumstances,

including systems development effort

and number of records.

• Burden hours for employees and

employers are not considered as part of

this request. Most of the information has

been collected from employees and

employers under the IRS new hire,

Form W–4 (OMB Control No. 1545–

0010), and/or comparable State forms.

In addition, ACF will not collect any

more information from employers or

employees under this pilot project than

what States have already collected.

Additional Information

ACF is requesting that OMB grant a 90

day approval for this information

collection under procedures for

emergency processing by July 11, 1996.

A copy of this information collection,

with applicable supporting

documentation, may be obtained by

calling the Administration for Children

and Families, Reports Clearance Officer,

Bob Sargis at (202) 401–6465.

Comments and questions about the

information collection described above

should be directed to Office of

Information and Regulatory Affairs,

Office of Management and Budget,

Paperwork Reduction Project, 725 17th

Street N.W., Washington, D.C. 20503,

Attn: Ms. Wendy Taylor, (202) 395–

7316.

Dated: June 24, 1996.

Larry Guerrero,

Director, Office of Information Management

Services.

[FR Doc. 96–16569 Filed 6–27–96; 8:45 am]

BILLING CODE 4184–01–M

Health Care Financing Administration

[HCFA–2744, HCFA–2746]

Agency Information Collection

Activities: Submission for OMB

Review; Comment Request

In compliance with the requirement

of section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995, the

Health Care Financing Administration

(HCFA), Department of Health and

Human Services, has submitted to the

Office of Management and Budget

(OMB) the following proposal for the

collection of information. Interested

persons are invited to send comments

regarding the burden estimate or any

other aspect of this collection of

information, including any of the

following subjects: (1) The necessity and

utility of the proposed information

collection for the proper performance of

the agency’s functions; (2) the accuracy

of the estimated burden; (3) ways to

enhance the quality, utility, and clarity

of the information to be collected; and

(4) the use of automated collection

techniques or other forms of information

technology to minimize the information

collection burden.

1. Type of Information Collection

Request: Reinstatement, with change, of

a previously approved collection for

which approval has expired; Title of

Information Collection: End Stage Renal

Disease Medical Information System

ESRD Facility Survey; Form No.:

HCFA–2744; Use: The ESRD Facility

Survey form is completed annually by

Medicare approved providers of dialysis

and transplant services. The HCFA–

2744 is designed to collect information

concerning treatment trends, utilization

of services and patterns of practice in

treating ESRD patients. Frequency:

Annually; Affected Public: Business or

other for-profit and Not-for-profit

institutions; Number of Respondents:

3,200; Total Annual Responses: 3,200;

Total Annual Hours Requested: 25,600.

2. Type of Information Collection

Request: Reinstatement, with change, of

a previously approved collection for

which approval has expired; Title of

Information Collection: End Stage Renal

Disease Death Notification; Form No.:

HCFA–2746; Use: The form is

completed by all Medicare approved

ESRD facilities upon the death of an

ESRD patient. Its primary purpose is to

collect fact and cause of death. Reports

of deaths are used to show cause of

death and demographic characteristics

of these patients. Frequency: On

occasion; Affected Public: Business or

other for-profit, Not-for-profit

institutions and Federal Government;

Number of Respondents: 2,900; Total

Annual Responses: 40,600; Total

Annual Hours Requested: 6,902.

To request copies of the proposed

paperwork collections referenced above,

E-mail your request, including your

address, to Paperwork@hcfa.gov, or call

the Reports Clearance Office on (410)

786–1326. Written comments and

recommendations for the proposed

information collections should be sent

within 30 days of this notice directly to

the OMB Desk Officer designated at the

following address: OMB Human

Resources and Housing Branch,

Attention: Allison Eydt, New Executive

Office Building, Room 10235,

Washington, D.C. 20503.

Dated: June 20, 1996.

Kathleen B. Larson,

Director, Management Planning and Analysis

Staff, Office of Financial and Human

Resources, Health Care Financing

Administration.

[FR Doc. 96–16604 Filed 6–27–96; 8:45 am]

BILLING CODE 4120–03–P
Federal Register / Vol. 61, No. 126 / Friday, June 28, 1996 / Notices 33753

National Institutes of Health

National Cancer Institute:

Opportunities for Cooperative

Research and Development

Agreements (CRADA) for the

Development of Green Fluorescent

Protein (GFP) Technology Applications

Currently the National Cancer

Institute (NCI) has identified at least five

applications for this technology; GFP

research products, gene therapy gene

expression, analysis, diagnostics, and

drug screening. The NCI is looking for

multiple CRADA Collaborators to

develop independently different aspects

of the GFP technology.

AGENCY: National Institutes of Health,

PHS, DHHS.

ACTION: Notice.

SUMMARY: Pursuant to the Federal

Technology Transfer Act of 1986 (FTTA,

15 U.S.C. 3710; Executive Order 12591

of April 10, 1987 as amended by the

National Technology Transfer and

Advancement Act of 1995), the National

Cancer Institute (NCI) of the National

Institutes of Health (NIH) of the Public

Health Service (PHS) of the Department

of Health and Human Services (DHHS)

seeks Cooperative Research and

Development Agreements (CRADA)

with pharmaceutical or biotechnology

companies to develop application of

GFP. Any CRADA for the biomedical

use of this technology will be

considered. The CRADAs would have

an expected duration of one (1) to five

(5) years. The goals of the CRADAs

include the rapid publication of

research results and their timely

commercialization of products,

diagnostics and treatments that result

from the research. The CRADA

Collaborators will have an option to

negotiate the terms of an exclusive or

nonexclusive commercialization license

to subject inventions arising under the

CRADAs.

ADDRESSES: Proposals and questions

about these CRADA opportunities may

be addressed to Steven P. Marquis,

Office of Technology Development,

National Cancer Institute-Frederick

Cancer Research and Development

Center, P.O. Box B, Frederic, MD

21702–1201, Telephone: (301) 846–

5465, Facsimile: (301) 846–6820.

Background information, including

abstracts and reprints, is available. In

addition, pertinent information not yet

publicly disclosed may be obtained

under a confidential disclosure

agreement.

Requests for license application form,

or other questions and comments

concerning the licensing of this

technology should be directed to Steven

M. Ferguson, Acting Chief, Infectious

Disease Branch, Office of Technology

Transfer, National Institutes of Health,

6011 Executive Boulevard, Suite 325,

Rockville, MD 20852–3804, Telephone:

(301) 496–7735 ext. 266, Facsimile:

(301) 402–0220. A signed

confidentiality agreement will be

required to receive confidential

information.

EFFECTIVE DATE: In view of the high

interest for developing GFP for

applications and diagnostics, interested

parties should notify the NCI Office of

Technology Development in writing no

later than thirty (30) days from the date

of this announcement. Respondents will

then be provided an additional thirty

(30) days for submitting formal CRADA

proposals.

SUPPLEMENTARY INFORMATION: The Green

Fluorescent Protein (GFP) from the

jellyfish Aequorea Victoria is rapidly

becoming an important reporter

molecule for monitoring gene

expression in vivo, in situ and in real

time GFP emits a green light when

excited with UV light. Unlike other

bioluminescent reporters, GFP

fluoresces in the absence of any other

proteins, substrates, or cofactors.

Currently there are several improved

mutations of the GFP, which allow for

sufficient detection of gene expression

in various species cells, However, the

current technology, in contrast to the

wild type protein or other reported

mutants allows detection of green

fluorescence in living mammalian cells

when present in few copies stably

integrated into the genome. The current

mutation increases the intensity of the

fluorescent signal by more than tenfold

over that of the wild type protein, which

provide a fluorescence signal visible in

mammalian cells.

A U.S. Patent Application has been

filed for this technology by the DHHS

and is currently pending. Parties

interested in submitting a CRADA

proposal should be aware that it may be

necessary to secure a license to this

patent application in order to

commercialize products arising from the

CRADA.

The role of the National Cancer

Institute in this CRADA will include,

but not be limited to:

1. Providing intellectual, scientific,

and technical expertise and experience

to the research project.

2. Planning research studies and

interpreting research results.

3. Contracting, as needed, support

services at the NCI–FCRDC such as

antigen and antibody production.

4. Publishing research results.

The role of the CRADA Collaborator

may include, but not limited to:

1. Providing significant intellectual,

scientific, and technical expertise or

experience to the research project.

2. Planning research studies and

interpreting research results.

3. Providing support for ongoing

CRADA-related research in the

development of the particular

application of GFP technology.

(a) Financial support to facilitate

scientific goals;

(b) Technical or financial support for

further design of applications.

4. Publishing research results.

Selection criteria for choosing the

CRADA Collaborator may include, but

not to be limited to:

1. The ability to collaborate with NCI

on further research and development of

this technology. This ability can be

demonstrated through experience and

expertise in this or related areas of

technology indicating the ability to

contribute intellectually to ongoing

research and development.

2. The demonstration of adequate

resources to perform the research,

development and commercialization of

this technology (e.g. facilities, personnel

and expertise) and accomplish

objectives according to an appropriate

timetable to be outlined in the CRADA

Collaborator’s proposal.

3.The willingness to commit best

effort and demonstrated resources to the

research, development and

commercialization of this technology.

4. The demonstration of expertise in

the commercial development,

production, marketing and sales of

products related to this area of

technology.

5. The level of financial support the

CRADA Collaborator will provide for

CRADA-related Government activities.

6. The willingness to cooperate with

the National Cancer Institute in the

timely publication of research results.

7. The agreement to be bound by the

appropriate DHHS regulations relating

to human subjects, and all PHS policies

relating to the use and care of laboratory

animals.

8. The willingness to accept the legal

provisions and language of the CRADA

with only minor modifications, if any.

These provisions govern the equitable

distribution of patent rights to CRADA

inventions. Generally, the rights of

ownership are retained by the

organization that is the employer of the

inventor, with (1) the grant of a license

for research and other Government

purpose to the Government when the

CRADA Collaborator’s employee is the

sole inventor, or (2) the grant of an

option to elect an exclusive or
33754 Federal Register / Vol. 61, No. 126 / Friday, June 28, 1996 / Notices

nonexclusive license to the CRADA

Collaborator when the Government

employee is the sole inventor.

Dated: June 18, 1996.

Thomas D. Mays,

Director, Office of Technology Development,

National Cancer Institute, National Institutes

of Health.

[FR Doc. 96–16493 Filed 6–27–96; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institutes; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings of the National Cancer

Institute Initial Review Group:

Agenda/Purpose: To review and evaluate

grant applications.

Committee Name: Subcommittee D—

Clinical Studies Subcommittee.

Dates: July 29–30, 1996.

Time: 8 a.m.

Place: Hyatt Regency Bethesda, One

Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: John W. Abrell, Ph.D.,

6130 Executive Blvd., Room 635B, Bethesda,

MD 20892, Telephone: 301–496–9767.

Committee Name: Subcommittee E—

Prevention and Control Subcommittee.

Date: July 30, 1996.

Time: 9 a.m.

Place: Hyatt Regency Hotel, One Bethesda

Metro, Bethesda, MD 20852.

Contact Person: Sally A. Mulhern, Ph.D.,

6130 Executive Blvd., Room 643G, Bethesda,

MD 20892, Telephone: 301–496–7413.

Committee Name: Subcommittee C—Basic

and Preclinical Sciences Subcommittee.

Dates: July 31–August 2, 1996.

Time: July 31–7:30 p.m.—August 1–2–8

a.m.

Place: Holiday Inn Georgetown, 2101

Wisconsin Avenue, N.W., Washington, D.C.

20007.

Contact Person: Virginia P. Wray, Ph.D.,

6130 Executive Blvd., Room 635, Bethesda,

MD 20892, Telephone: 301–496–9236.

Committee Name: Subcommittee A—

Cancer Centers Subcommittee.

Dates: August 1–2, 1996.

Time: 8 a.m.

Place: The Bethesda Ramada, 8400

Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: David E. Maslow, Ph.D.,

6130 Executive Blvd., Room 643A, Bethesda,

MD 20892, Telephone: 301–496–2330.

The meetings will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)

Dated: June 21, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–16492 Filed 6–27–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Dental Research;

Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute of Dental Research

Special Emphasis Panel (SEP) meetings:

Name of SEP: National Institute of Dental

Research Special Emphasis Panel—Review of

RFP No. NLM 96–100/MLM (96–35).

Dates: July 15–16, 1996.

Time: 8:00 a.m.

Place: Holiday Inn/Chevy Chase, 5520

Wisconsin Avenue, Chevy Chase, MD 20815.

Contact person: Dr. George Hausch, Chief,

Grants Review Section, 4500 Center Drive,

Natcher Building, Room 4AN–44F, Bethesda,

MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review

grant applications and/or contract proposals.

Name of SEP: National Institute of Dental

Research Special Emphasis Panel—Project

Site Visit (96–30).

Dates: July 18–19, 1996.

Time: 8:00 a.m.

Place: San Francisco Downtown Marriott,

55 Fourth Street, San Francisco, CA 94103.

Contact Person: Dr. George Hausch, Chief,

Grants Review Section, 4500 Center Drive,

Natcher Building, Room 4AN–44F, Bethesda,

MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review

grant applications and/or contract proposals.

Name of SEP: National Institute of Dental

Research Special Emphasis Panel—Review of

R44’s (96–28)

Dates: July 30, 1996.

Time: 12:00 Noon.

Place: National Institutes of Health, 4500

Center Drive, Natcher Building, Room 4AN–

44F, Bethesda, MD 20892, (Teleconference).

Contact person: Dr. George Hausch, Chief,

Grants Review Section, 4500 Center Drive,

Natcher Building, Room 4AN–44F, Bethesda,

MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review

grant applications and/or contract proposals.

Name of SEP: National Institute of Dental

Health Research Special Emphasis Panel—

Review of RFA DE–96–003 (96–31).

Dates: August 5–6, 1996.

Time: 8:00 a.m.

Place: Cross Keys Inn, 5100 Falls Road,

Baltimore, MD 21210.

Contact person: Dr. Yong Shin, Grants

Review Section, 4500 Center Drive, Natcher

Building, Room 4AN–44F, Bethesda, MD

20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review

grant applications and/or contract proposals.

The meetings will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program No. 93.121, Oral Diseases and

Disorders Research)

Dated: June 21, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–16491 Filed 6–27–96; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

[Docket No. FR–3454–N–02]

Office of the Assistant Secretary for

Housing-Federal Housing

Commissioner; Capital Improvement

Loans Under the Flexible Subsidy

Program Awarded as Incentives

Pursuant to Preservation Plans of

Action, Announcement of Funding

Awards; Fiscal Year 1993

AGENCY: Office of the Assistant

Secretary for Housing - Federal Housing

Commissioner, HUD.

ACTION: Announcement of funding

awards.

SUMMARY: In accordance with section

102(a)(4)(C) of the Department of

Housing and Urban Development

Reform Act of 1989, this announcement

notifies the public of funding awards

made by the Department for funding

under a Federal Register Notice of

Funding Availability (NOFA) for the

Capital Improvement Loan Program.

This announcement contains the names

and addresses of the awardees and the

amount of the awards.

FOR FURTHER INFORMATION CONTACT:

Ruth Coward, Program Support

Division, Office of Multifamily Asset

Management and Disposition, Office of

Housing, Department of Housing and

Urban Development, 451 Seventh Street,

SW, Washington, DC 20410, telephone

(202) 708–2654. (This is not a toll-free

number.) Hearing- or speech-impaired

individuals may access this number by

calling the Federal Information Relay

Service TTY at 1–800–877–8339.

SUPPLEMENTARY INFORMATION: The

Flexible Subsidy Program is authorized